share_log

argenx SE | 6-K: argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

SEC announcement ·  Mar 27 06:18
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more